Core Insights - The stock price of Aorite has decreased by 2.15% on October 13, trading at 22.31 CNY per share with a market capitalization of 9.062 billion CNY [1] - Aorite's stock has increased by 7.10% year-to-date, with a slight decline of 0.09% over the last five trading days and a 3.55% drop over the last 20 days [2] Company Overview - Aorite Pharmaceutical Co., Ltd. is located in Tiantai County, Zhejiang Province, established on March 5, 1998, and listed on September 21, 2020 [2] - The company's main business involves the research, production, and sales of specialty raw materials and pharmaceutical intermediates, with revenue composition as follows: 85.12% from raw materials and intermediates, 11.64% from finished drugs, 2.74% from import and export trade, and 0.50% from other sources [2] - Aorite belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and raw material drug sector, with concepts including pharmaceutical e-commerce, assisted reproduction, raw materials, peptide drugs, and synthetic biology [2] Financial Performance - For the first half of 2025, Aorite achieved operating revenue of 822 million CNY, representing a year-on-year growth of 12.50%, and a net profit attributable to shareholders of 235 million CNY, up 24.55% year-on-year [2] - The company has distributed a total of 372 million CNY in dividends since its A-share listing, with 272 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, Aorite had 11,800 shareholders, an increase of 7.86% from the previous period, with an average of 33,770 circulating shares per shareholder, a decrease of 7.29% [2]

格隆汇10月9日丨奥锐特(605116.SH)公布，截至2025年9月30日，公司通过上海证券交易所交易系统以 集中竞价交易方式已累计回购公司股份174.67万股，占公司目前总股本的比例为0.43%，回购成交的最 高价为22.59元/股，最低价为18.83元/股，支付的资金总额为人民币3560.75万元（不含交易费用）。 ...

Group 1 - Company Aorite (SH 605116) announced a share buyback of approximately 1.75 million shares, representing 0.43% of its total share capital, with a total expenditure of about 35.61 million RMB [1] - The highest buyback price was 22.59 RMB per share, while the lowest was 18.83 RMB per share [1] - For the first half of 2025, Aorite's revenue composition was as follows: 85.12% from self-produced raw materials and intermediates, 11.64% from formulations, 2.74% from trading, and 0.5% from other businesses [1] Group 2 - Aorite's market capitalization is currently 9.2 billion RMB [2]

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 2025 年 1 月 21 日，奥锐特药业股份有限公司（以下简称"公司"）召开第三 届董事会第十二次会议，会议以 9 票同意、0 票反对、0 票弃权审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以集中竞价交易方式回 购公司股份，回购的股份全部用于转换公司可转债。本次回购股份的资金总额为 不低于人民币 6,000 万元（含），不高于人民币 12,000 万元（含），回购价格不超 过人民币 25.00 元/股（含），回购期限自公司董事会审议通过回购方案之日起不 超过 12 个月。 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《奥锐 特药业股份有限公司关于以集中竞价交易方式回购股份方案的公告》（公告编号： 2025-005）、《奥锐特药业股份有限公司关于以集中竞价交易方式回购股份的回购 报告书》（公告编号：2025-007）。 2025 年 5 月 16 ...

关于可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 9 月 30 日，累计已有面值 8,000 元"奥锐 转债"转为公司 A 股普通股，累计转股股数为 313 股，占"奥锐转债"转股前 公司已发行普通股股份总额的 0.0001%。 未转股可转债情况：截至 2025 年 9 月 30 日，尚未转股的"奥锐转债" 面值为人民币 812,112,000 元，占"奥锐转债"发行总量的比例为 99.9990%。 证券代码：605116 证券简称：奥锐特 公告编号：2025-074 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 本季度转股情况："奥锐转债"自 2025 年 2 月 5 日起可转换为公司股票， 2025 年 7 月 1 日至 2025 年 9 月 30 日期间无转股。 一、可转债发行上市概况 （一）可转债发行情况 经中国证券监督管理委员会《关于同意奥锐特药业股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可〔 ...

Core Viewpoint - The board of Aurite Pharmaceutical Co., Ltd. has approved a share repurchase plan to buy back shares through centralized bidding, with a budget of 60 million to 120 million yuan for the purpose of converting the company's convertible bonds [1] Summary by Relevant Sections - **Repurchase Plan Details** - The repurchase amount is set between 60 million and 120 million yuan, with a repurchase period of 12 months [1] - The upper limit for the repurchase price was originally not to exceed 25 yuan per share, adjusted to not exceed 24.71 yuan per share after equity distribution [1] - **Current Repurchase Status** - As of September 30, the company has repurchased a total of 1,746,738 shares, accounting for 0.43% of the total share capital [1] - The total funds paid for the repurchase amount to 35,607,509.68 yuan, with a repurchase price range between 18.83 and 22.59 yuan per share [1]

Report Summary - The report presents the top ten convertible bonds for October 2025, along with an analysis of the issuing companies, including their business profiles, financial performance, and key attractions [13][23][35] Top Ten Convertible Bonds in October 2025 1. Zhongte Convertible Bond - Rating: AAA; 9 - month - end closing price: 112.896 yuan; Conversion premium rate: 85.92%; PE - TTM of the underlying stock: 13.22 [7][13] - Company: A globally leading specialized special - steel material manufacturer with a production capacity of about 20 million tons of special - steel materials per year. It has multiple production and raw - material bases, forming a strategic layout along the coast and rivers [13] - Financials: In 2024, revenue was 109.203 billion yuan (YoY - 4.22%), net profit attributable to shareholders was 5.126 billion yuan (YoY - 10.41%). In H1 2025, revenue was 54.715 billion yuan (YoY - 4.02%), net profit attributable to shareholders was 2.798 billion yuan (YoY + 2.67%) [13] - Key attractions: It is one of the world's most comprehensive special - steel enterprises in terms of variety and specification, with leading cost - control ability and potential for external expansion [14] 2. Shanlu Convertible Bond - Rating: AAA; 9 - month - end closing price: 119.346 yuan; Conversion premium rate: 48.74%; PE - TTM of the underlying stock: 4.08 [7][23] - Company: Mainly engaged in road and bridge construction and maintenance, and also expanding into other fields. It can provide one - stop comprehensive services [23] - Financials: In 2024, revenue was 71.348 billion yuan (YoY - 2.3%), net profit attributable to shareholders was 2.322 billion yuan (YoY + 1.47%). In H1 2025, revenue was 28.575 billion yuan (YoY + 0.26%), net profit attributable to shareholders was 1.029 billion yuan (YoY + 0.89%) [23] - Key attractions: It has the concept of "China - specific valuation", potential for improvement in various aspects under the debt - resolution background, and opportunities from regional infrastructure construction and the Belt and Road Initiative [24] 3. Hebang Convertible Bond - Rating: AA; 9 - month - end closing price: 126.41 yuan; Conversion premium rate: 21.55%; PE - TTM of the underlying stock: - 168.47 [7][35] - Company: With advantages in mineral resources and gas supply, it has completed a basic layout in the chemical, agricultural, and photovoltaic fields [35] - Financials: In 2024, revenue was 8.547 billion yuan (YoY - 3.13%), net profit attributable to shareholders was 31 million yuan (YoY - 97.55%). In H1 2025, revenue was 3.921 billion yuan (YoY - 19.13%), net profit attributable to shareholders was 52 million yuan (YoY - 73.07%) [35] - Key attractions: Its phosphate mines and salt mines have good profit - making potential, and the liquid methionine business is a major profit contributor [36] 4. Aima Convertible Bond - Rating: AA; 9 - month - end closing price: 128.513 yuan; Conversion premium rate: 38.62%; PE - TTM of the underlying stock: 13.41 [7][45] - Company: The leading enterprise in the electric two - wheeled vehicle industry, mainly engaged in R & D, production, and sales of electric two - wheeled vehicles [45] - Financials: In 2024, revenue was 21.606 billion yuan (YoY + 2.71%), net profit attributable to shareholders was 1.988 billion yuan (YoY + 5.68%). In H1 2025, revenue was 13.031 billion yuan (YoY + 23.04%), net profit attributable to shareholders was 1.213 billion yuan (YoY + 27.56%) [45] - Key attractions: It may benefit from government subsidies, new national standards, and potential improvement in gross margin [46] 5. Xingye Convertible Bond - Rating: AAA; 9 - month - end closing price: 120.859 yuan; Conversion premium rate: 29.02%; PE - TTM of the underlying stock: 5.43 [7][54] - Company: One of the first joint - stock commercial banks in China, evolving into a modern financial service group [54] - Financials: In 2024, revenue was 212.226 billion yuan (YoY + 0.66%), net profit attributable to shareholders was 77.205 billion yuan (YoY + 0.12%). In H1 2025, revenue was 110.458 billion yuan (YoY - 2.29%), net profit attributable to shareholders was 43.141 billion yuan (YoY + 0.21%) [54] - Key attractions: It has stable asset quality and scale growth [55] 6. Wentai Convertible Bond - Rating: AA -; 9 - month - end closing price: 128.918 yuan; Conversion premium rate: 20.93%; PE - TTM of the underlying stock: - 23.14 [7][66] - Company: A globally leading semiconductor enterprise adopting the IDM model, providing R & D, manufacturing, and testing services [66] - Financials: In 2024, revenue was 73.598 billion yuan (YoY + 20.23%), net profit attributable to shareholders was - 2.833 billion yuan (YoY - 339.83%). In H1 2025, revenue was 25.341 billion yuan (YoY - 24.56%), net profit attributable to shareholders was 474 million yuan (YoY + 237.36%) [66] - Key attractions: After focusing on the semiconductor business, it benefits from market recovery and has growth potential in the automotive and consumer electronics fields [67] 7. Chongyin Convertible Bond - Rating: AAA; 9 - month - end closing price: 121.778 yuan; Conversion premium rate: 31.87%; PE - TTM of the underlying stock: 5.88 [7][77] - Company: An early local joint - stock commercial bank in the upper reaches of the Yangtze River and Southwest China, with a wide range of business scopes [77] - Financials: In 2024, revenue was 13.679 billion yuan (YoY + 3.54%), net profit attributable to shareholders was 5.117 billion yuan (YoY + 3.8%). In H1 2025, revenue was 7.659 billion yuan (YoY + 7%), net profit attributable to shareholders was 3.19 billion yuan (YoY + 5.39%) [77] - Key attractions: It can benefit from the development of the Chengdu - Chongqing economic circle, has stable asset - scale growth, and effective risk - control strategies [78] 8. Tianye Convertible Bond - Rating: AA +; 9 - month - end closing price: 120.562 yuan; Conversion premium rate: 48.06%; PE - TTM of the underlying stock: 146.42 [7][89] - Company: A leading enterprise in the chlor - alkali chemical industry in Xinjiang, with an integrated circular economy industrial chain [89] - Financials: In 2024, revenue was 11.156 billion yuan (YoY - 2.7%), net profit attributable to shareholders was 68 million yuan (YoY + 108.83%). In H1 2025, revenue was 5.16 billion yuan (YoY - 0.98%), net profit attributable to shareholders was - 9 million yuan (YoY - 228.22%) [89] - Key attractions: It may benefit from the price change of caustic soda and has plans for dividend increase and coal - mine projects [90] 9. Aorui Convertible Bond - Rating: AA -; 9 - month - end closing price: 126.412 yuan; Conversion premium rate: 40.56%; PE - TTM of the underlying stock: 22.72 [7][100] - Company: A company focusing on the R & D, production, and sales of complex APIs and preparations, with leading positions in multiple fields [100] - Financials: In 2024, revenue was 1.476 billion yuan (YoY + 16.89%), net profit attributable to shareholders was 355 million yuan (YoY + 22.59%). In H1 2025, revenue was 822 million yuan (YoY + 12.5%), net profit attributable to shareholders was 235 million yuan (YoY + 24.55%) [100] - Key attractions: It has a growing dealer network, expanding preparation products, and high - quality customer resources [101] 10. Yushui Convertible Bond - Rating: AAA; 9 - month - end closing price: 125.081 yuan; Conversion premium rate: 30.74%; PE - TTM of the underlying stock: 26.93 [7][108] - Company: The largest integrated water supply and drainage enterprise in Chongqing, with a stable monopoly position [108] - Financials: In 2024, revenue was 6.999 billion yuan (YoY - 3.52%), net profit attributable to shareholders was 785 million yuan (YoY - 27.88%). In H1 2025, revenue was 3.519 billion yuan (YoY + 7.16%), net profit attributable to shareholders was 458 million yuan (YoY + 10.06%) [108] - Key attractions: It has a high market share, is expanding business externally, and has effective cost - control measures [109]

Core Points - The company held its first extraordinary general meeting of shareholders on September 26, 2025, with no resolutions rejected [2][3] - The meeting was conducted in accordance with relevant laws and regulations, including the Company Law and the company's articles of association [2][5] - The company approved several key resolutions, including the appointment of the 2025 annual audit firm and the cancellation of the supervisory board [3][21] Group 1: Shareholder Meeting - The meeting was held at the company's administrative building in Zhejiang Province, with a combination of on-site and online voting [2] - The chairman of the board, Mr. Peng Zhien, presided over the meeting, which complied with legal requirements [2][3] - All proposed resolutions were passed, including the appointment of the audit firm and amendments to the company's articles of association [3][4] Group 2: Employee Representative Meeting - The employee representative meeting took place on September 25, 2025, with 98 out of 100 representatives present [9] - The meeting approved the removal of the employee representative supervisor and the election of an employee representative director [10][11] - Mr. Li Jinliang was elected as the employee representative director, serving until the end of the current board's term [11] Group 3: Shareholder Reduction Announcement - Prior to the reduction plan, the company had a total of 406,195,234 shares, with major shareholders holding 41.88% [15] - The reduction plan involved a maximum of 2,176,600 shares, representing 0.54% of the total shares [16] - The reduction was completed, with the major shareholder retaining 7,730,600 shares, or 1.90% of the total [17] Group 4: Board Meeting - The board meeting was held on September 26, 2025, with 8 out of 9 directors present [20] - The board elected Mr. Peng Zhien as the representative director and legal representative of the company [20] - The board also established an audit committee and made adjustments to the organizational structure, eliminating the supervisory board [21][23]

Core Viewpoint - The company announced a share reduction plan by its controlling shareholder, which has been successfully executed, resulting in a decrease in the shareholder's stake in the company [1] Group 1: Share Reduction Details - The controlling shareholder, Tian Tai Bo Rong Investment Partnership (Limited Partnership), plans to reduce its holdings by up to 2.1766 million shares, representing 0.54% of the company's total share capital [1] - As of September 27, 2025, the shareholder has completed the reduction of 2.1766 million shares, leaving them with 7.7306 million shares, which is 1.90% of the total share capital [1] - The actual price range during the reduction period was between 21.90 and 22.85 yuan per share [1]

证券代码：605116 证券简称：奥锐特 公告编号：2025-072 债券代码：111021 债券简称：奥锐转债 减持计划的实施结果情况 公司于 2025 年 8 月 30 日披露《奥锐特药业股份有限公司股东减持股份计划 公告》（公告编号：2025-063），天台铂融为公司的员工持股平台，因部分合伙人 自身资金需求，自本公告发布之日起 15 个交易日后的 3 个月内（窗口期不减持）， 天台铂融拟通过集中竞价、大宗交易方式减持公司股份不超过 2,176,600 股，即 不超过公司总股本的 0.54%。 公司实际控制人不参与本次减持。 奥锐特药业股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，奥锐特药业股份有限公司（以下简称"公司"）的股 份总数为 406,195,234 股，天台铂融投资合伙企业（有限合伙）（以下简称"天 台铂融"）及其一致行动人浙江桐本投资有限公司（以下简称"浙江桐本"）、天 台铂恩投资管理合伙企业（有限合伙 ...